Last week I reported on two clinical trials, Pfizer's figitumumab and Novelos Therapeutics NOV-002 ,that failed to meet their end points for the treatment of non-small cell lung cancer (NSCLC).
Yesterday, as reported in PBR, Roche received a positive opinion from the European Committee for Medicinal Products (CHMP) for Human Use for the use of Tarceva (erlotinib) as a maintenance therapy for NSCLC patients. This should clear the way for earlier approval.
In the trial, patients receiving Tarceva showed improvement in terms of slower disease progression and greater overall survival rates. Approval of the drug will allow patients earlier access to it and its potential benefits.
So, some good news for a change for NSCLC patients.